Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy
Status:
Not yet recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR
T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult
patients with DLBCL who are scheduled to receive CD19-directed CAR T-cell therapy.
The first phase of the study will be open label with dose escalation. Participants will start
taking CTO1681 just prior to receiving their CAR T-cell therapy and continue to take the
study drug three times daily for a total of 15 days.